Arcus Biosciences Announces New Employment Inducement Grants

Core Insights - Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer patients [1] Company Actions - The Compensation Committee of the Company's Board of Directors granted options to purchase a total of 19,300 shares of common stock to three new employees [1] - The exercise price per share for these options is set at $12.19, which reflects the closing price on September 8, 2025 [1]